InvestSMART

Bionomics Limited (ASX: BNO) - Announcements

DELISTED - Current share price for BNO : $0.010

ASX company news and announcements for Bionomics Limited (BNO) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Bionomics Limited (BNO) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Bionomics Limited (BNO), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Bionomics Limited (BNO)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Bionomics` 2010/2011 Preliminary Final Results 18 Aug 2011 9:37AM $0.445 $0.010 fallen by 97.75%
- BNC105 Clinical Trials Reach Key Milestones 3 Aug 2011 9:33AM $0.600 $0.010 fallen by 98.33%
- Appendix 4C - quarterly 29 Jul 2011 8:22AM $0.485 $0.010 fallen by 97.94%
- Phase I BNC105 Clinical Trial Published 23 Jun 2011 9:55AM $0.570 $0.010 fallen by 98.25%
- Merck Serono Extends MS Collaboration with Bionomics 9 Jun 2011 9:34AM $0.660 $0.010 fallen by 98.48%
- BNC105 Renal Cancer Trial To Be Presented AT ASCO 3 Jun 2011 9:48AM $0.640 $0.010 fallen by 98.44%
- Open Briefing - Outlook and Strategic Focus 25 May 2011 11:21AM $0.720 $0.010 fallen by 98.61%
- Successful Register Repositioning Complete 13 May 2011 10:09AM $0.630 $0.010 fallen by 98.41%
- Trading Halt 12 May 2011 10:21AM $0.720 $0.010 fallen by 98.61%
- Start-up Australia Ventures Sells 60 Millions BNO Shares 12 May 2011 10:15AM $0.720 $0.010 fallen by 98.61%
- BNC210 - Further Validation 10 May 2011 10:18AM $0.695 $0.010 fallen by 98.56%
- BNO Sells Thebarton Premises to Boost Cash Reserves 4 May 2011 9:29AM $0.560 $0.010 fallen by 98.21%
- Appendix 4C - quarterly 29 Apr 2011 3:44PM $0.690 $0.010 fallen by 98.55%
- Response to ASX Price Query 13 Apr 2011 5:37PM $0.710 $0.010 fallen by 98.59%
- Invitation to Tender for Shares 30 Mar 2011 6:45PM $0.510 $0.010 fallen by 98.04%
- Anti-Anxiety Drug Clinical Trials Successful Results 30 Mar 2011 9:37AM $0.510 $0.010 fallen by 98.04%
- Trading Halt 28 Mar 2011 9:49AM $0.430 $0.010 fallen by 97.67%
- Half Yearly Report and Accounts 11 Feb 2011 4:01PM $0.595 $0.010 fallen by 98.32%
- Patent Applications Filed on Compounds to Treat Memory Loss 4 Feb 2011 10:31AM $0.375 $0.010 fallen by 97.33%
- Appendix 4C - quarterly 31 Jan 2011 10:52AM $0.500 $0.010 fallen by 98%
- Open Briefing - CEO on Company Update and BNC210 Results 25 Nov 2010 10:07AM $0.325 $0.010 fallen by 96.92%
- Invitation to tender for the purchase of 27.76% of shares 10 Nov 2010 5:35PM $0.315 $0.010 fallen by 96.83%
- Appendix 4C - quarterly 27 Oct 2010 10:20AM $0.320 $0.010 fallen by 96.88%
- BNC210 - European Approval Granted for Two Phase Ib Trials 5 Oct 2010 9:43AM $0.270 $0.010 fallen by 96.30%
- Open Briefing - BNO CEO on BNC210 Clinical Trials 2 Sep 2010 9:24AM $0.260 $0.010 fallen by 96.15%

626 - 650 of 801 results

Page 26 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.